Free Newsletter
Novartis, Novo sue Bayer over patent
Novartis and Novo Nordisk are ganging up on Bayer, alleging that the German company's hemophilia treatment Kogenate infringes on one of their joint patents. In a statement, Bayer said it would "vigorously defend itself" against the complaint, and that it doesn't believe it has overstepped the bounds of any patents. The company's stock fell on the news. Meanwhile, other news reports said the suit, filed in federal court in Texas, names Wyeth as well. The New Jersey-based firm has not yet commented.
- see Bayer's release
- read the article at CNN Money
- check out reports of the Wyeth connection at CNN Money
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: